Clinical Trial: Diabetes Telemedicine Consultation: a Systems Improvement Intervention
This study is not yet open for patient recruitment.
| Sponsored by: | Department of Veterans Affairs | | Information provided by: | Department of Veterans Affairs | |
Purpose
Diabetes is a national problem that has reached epidemic proportions, according to the U.S. Centers for Disease Control and Prevention.
Diabetes has particular importance for the Department of Veterans Affairs (VA) because the prevalence among VA patients -- one in six, or 16 percent -- is substantially higher than in the general population. The immediate objective is to evaluate and document the processes of outreach consultation through using joint-clinics via teleconferencing as an
intervention for system improvement in care delivery and management of
diabetes at Community Based
Outpatient Clinics (CBOCs). The
intervention consists of a teleconferenced joint-clinic consultation session involving the patient,
Diabetes Specialist Team, the primary care physician (PCP) and other relevant care team members. The impact of the
intervention will be assessed using both high-risk patients who are referred to a
diabetes specialist for consultation during the 18-month active
intervention phase (Cohort I) and other patients with
diabetes who are not referred during the
intervention phase (Cohort II). The specific aims are: (1) compare the impact of
diabetes specialist joint-clinic consultations via teleconferencing conducted at CBOCs to the usual consultation process on referred high-risk Cohort I patients and providers; (2) compare the impact of
diabetes joint-clinic consultations via teleconferencing to usual consultation process on outcomes related to providers’ care of other patients (non-Cohort I patients); (3) compare processes and change in processes associated with
diabetes specialist joint-clinic consultations to usual
outpatient consultation process for patients with
diabetes using qualitative and quantitative methods (microsystem factors); (4) evaluate short-term medical care utilization and costs associated with the intervention. The long-term objectives are to improve the quality of care delivered and decrease diabetes-related complications. Study settings include the CBOCs and involves primary care referrals to see
diabetes specialists at the Cleveland VAMC. Inclusion criteria for Cohort I patients are: (i) current
prescription of
insulin or an
oral hypoglycemic agent; (ii) A1c > 7.0%; or (iii) fasting
glucose levels > 130 mg/dl; and (iv) referred to see a consultant (beginning three months prior to the active
intervention phase and continuing through enrollment for the last month of the active
intervention phase). Patients with either Type I or Type II
diabetes will be included. Patients referred will be contacted and asked to participate (N=710 anticipated to complete the study). Cohort II patients will be determined by the above criteria minus referral (N=10,270). All PCP/PC CBOC team members (N=90) and CBOC staff involved in the care of patients will be asked to participate.
| Condition | Intervention |
Diabetes Mellitus Type 2 Diabetes Mellitus Type 1
| Behavior: The Diabetes Treatment Satisfaction Questionnaire Behavior: Diabetes Empowerment Scale Behavior: CBOC''''s will undergo half-day joint-clinics with the Diabetes Expert Team via teleconferencing
|
MedlinePlus related topics: Diabetes; Juvenile Diabetes
Study Type: Interventional
Study Design: Educational/Counseling/Training, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Further Study Details:
Expected Total Enrollment: 2
Study start: April 2005; Expected completion: March 2009
During the
intervention phase CBOC''''s will undergo half-day joint-clinics with the
Diabetes Expert Team via teleconferencing.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
- Current prescription of insulin or an oral hypoglycemic agent;
- A1c > 7.0%; -OR- fasting glucose levels > 130 mg/dl
- Referred to see a consultant and are seen during the active intervention phase.
- Patients with either Type I or Type II DM will be included.
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00119041
Ohio Louis Stokes VA Medical Center, Cleveland, Ohio, 44106-3800, United States
David C. Aron, MD MS (216)791-3800 4110 david.aron@med.va.gov
More Information
Publications
Aron DC. Cushing''''s syndrome from bedside to bench and back: a historical perspective. Endocrinol Metab Clin North Am. 2005 Jun;34(2):257-69, vii.
Study ID Numbers: IIR 03-254
Record last reviewed: July 2005
Last Updated: July 25, 2005
Record first received: July 11, 2005
ClinicalTrials.gov Identifier: NCT00119041
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-07-26
Source: ClinicalTrials.gov
Cache Date: July 27, 2005